Omicron BA.5 makes up 82% of Covid variants in U.S. - CDC | Inquirer
 
 
 
 
 
 

Omicron BA.5 makes up 82% of Covid variants in U.S. – CDC

/ 08:47 AM July 26, 2022

People wait to take coronavirus disease (COVID-19) tests at a pop-up testing site in New York City, U.S., July 11, 2022. REUTERS/Brendan McDermid/File Photo

People wait to take coronavirus disease (COVID-19) tests at a pop-up testing site in New York City, U.S., July 11, 2022. REUTERS/Brendan McDermid/File Photo

The BA.5 subvariant of Omicron was estimated to make up 81.9% of the circulating coronavirus variants in the United States for the week ended July 23, the U.S. Centers for Disease Control and Prevention (CDC) said on Tuesday.

This was higher than the 75.9% prevalence estimated in the preceding week.

BA.5 has been driving a surge of new infections globally and has shown to be particularly good at evading the immune protection afforded either by vaccination or prior infection.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

Omicron subvariant BA.4 was estimated to make up 12.9% of the circulating variants in the United States, the data showed.

The U.S. Food and Drug Administration has asked vaccine manufacturers to target the two currently dominant subvariants for a potential fall season booster dose.

U.S. health officials are also urging people aged 50 or more to get a booster shot, adding that doing so would not prevent them from getting another “bivalent” booster designed to fend off Omicron more specifically later this year.

Want stories like this delivered straight to your inbox? Stay informed. Stay ahead. Subscribe to InqMORNING

Don't miss out on the latest news and information.
TAGS: COVID-19
For feedback, complaints, or inquiries, contact us.
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.




This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.